1AD
Director Trades
| Date | Director | Value |
|---|---|---|
| 3/6/25 | T. Oldham | $35,000 |
| 3/6/25 | P. MacLeman | $213 |
| 3/6/25 | D. Fuller | $1,000 |
| 3/6/25 | I. Ross | $11,520 |
Company News
Market wrap: big banks send ASX into record territory
Australia’s big banks have pushed the ASX 200 to a record close of 7847 points after more signs of lower inflation in major economies caused a global relief rally. With interest rates now looking almost a certainty to fall in the big markets of the US, Europe and Australia, investors celebrated hard with a fresh […]
AdAlta’s AD-214 demonstrates safety and efficacy potential for fibrotic disease treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies. The results are reported to have also positively answered key questions from pharmaceutical partner companies in support […]
AdAlta completes patient recruitment for AD-214 study to treat debilitating diseases
Clinical stage drug discovery company AdAlta (ASX: 1AD) has completed the recruitment of healthy volunteers to its Phase I extension study of lead candidate AD-214 to treat debilitating and fatal scarring diseases including idiopathic pulmonary fibrosis (IPF). The study is designed to assess the safety and availability of multiple intravenous doses measuring 10 milligrams per […]
AdAlta secures licencing deal for i-body platform with US giant GE Healthcare
Biotech company AdAlta (ASX: 1AD) signed taken a significant towards monetising its proprietary technology after signing a commercial agreement for its i-body platform with US-based medical technology giant, GE Healthcare. However, despite making the announcement earlier today, the company stopped short of publishing financial terms. GE Healthcare is an American multinational conglomerate that currently generates […]
AdAlta courts big pharma with ‘enhanced’ anti-fibrosis drug, locks-in manufacturing agreements
AdAlta (ASX: 1AD) is a step closer to clinical trial stage after it locked-in critical manufacturing agreements for its lead anti-fibrosis AD-214 drug, which is an “enhanced” version of the precursor AD-114. The new AD-214 was launched in April and retains the original’s unique therapeutic benefits, making it more attractive to potential big pharma suitors. […]
